Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
JNJ · against 1,339 other Healthcare companies
Ranked #530 of 1,340 · scores higher than 60% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 60–69, including JNJ · Click a bar to see the companies
Mainly thanks to its free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | JNJ | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 3.3% | 1.4% | 65% | 30% | |
| EBITDA yieldHigher is better · 1,359 reported | 5.4% | 4.1% | 58% | 50% | |
| Free cash flow yieldHigher is better · 700 reported | 3.6% | -1.1% | 71% | 20% | |
| Book yieldHigher is better · 1,237 reported | 13.7% | 34.8% | 20% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.2B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.2B HKD (≈$151M) | 99 | 72 | |
| 1 | 14.6B HKD (≈$1.9B) | 99 | 64 | |
| 1 | 46.3B HKD (≈$5.9B) | 99 | 56 | |
| 1 | 4.8B HKD (≈$612M) | 99 | 51 | |
| 530 | 5.2B CNY (≈$725M) | 60 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 70 |
| 530 | 471M NZD (≈$283M) | 60 | 64 |
| 530 | 784M USD | 60 | 34 |
| 530 | 22.9B USD | 60 | 60 |
| 530 | 622.8B USD | 60 | 59 |
| 530 | 1.8B USD | 60 | 79 |
| 530 | 4.9B NOK (≈$465M) | 60 | 72 |
| 530 | 5.1B USD | 60 | 61 |
| 530 | 5.5B SEK (≈$545M) | 60 | 60 |